Antares Pharma Earnings: Here’s Why Investors are Ambivalent Now

Antares Pharma Inc (NASDAQ:ATRS) had a loss and met Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Antares Pharma Inc Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.03 in the quarter versus EPS of $0.00 in the year-earlier quarter.

Revenue: Decreased 34.4% to $4.5 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: reported adjusted EPS loss of $0.03 per share. By that measure, the company missed the mean analyst estimate of $-0.03. It missed the average revenue estimate of $5.12 million.

Quoting Management: There was no comment from the management.

Key Stats (on next page)…

Revenue decreased 18.18% from $5.5 million in the previous quarter. EPS decreased to $-0.03 in the quarter versus EPS of $-0.04 in the previous quarter.

Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.01 to a loss $0.03. For the current year, the average estimate has moved down from a loss of $0 to a loss of $0.11 over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)